People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

Deceased organ donation covers our organ needs. In India, we are woefully short of organs such as kidneys and livers in cases of liver and kidney failure that need to be transplanted.

Deceased donation, as the name sounds, is a donation by people who are brain dead, whose family has now accepted and has willingly donated their organs for the benefit of the rest of the world.

Live donation, on the other hand, is a donation by living or emotionally related individuals who want to donate a kidney to a diseased patient. A live donation is usually transplanted immediately. It's done in the same centre, and both are done together, as the harvesting of the organ from the donor and transplantation are done simultaneously.

On the other hand, a deceased organ from a cadaveric donor may be harvested in a different geographical location and may be transported over time and over a lot of distance to another centre.

Deceased donation can be done for organs that cannot be transplanted by live donation, which are so consequential to a human body, such as the heart, lungs, and pancreas. They are very vital and cannot be transplanted from a live patient to another.

In a deceased organ donation, we can even donate tissues such as the cornea, skin, and blood vessels, which are required as a part of donation, as a part of other organ donation transplant programmes or, for example, in giving vision to people who have a white cornea or corneal opacity.

These are a few differences between live and deceased or cadaveric donation.

Dr. Vikram Shah Batra, Director - Urology, Kidney Transplant and Uro Oncology, Max Super Speciality Hospital, Dwarka

A uterine growth diagnosis can be very alarming. That said, it is vital to note that such growths are often simple, run-of-the-mill fibroids. They are non-cancerous, very common, and completely harmless. At the same time, it is important to realise what uterine sarcoma is, and why fibroids are often confused with uterine sarcoma. It comes down to anatomy. The uterus consists mainly of smooth muscle tissue. A fibroid is just an overgrowth of this smooth muscle that expands over time. Uterine sarcoma is a rare cancer that originates within that very same muscle wall. Since both develop in the same spot, they tend to trigger identical symptoms—like unexpected bleeding, pelvic aching, or pressure.

Why Accurate Diagnosis Matters Before Surgery

Before starting treatment, it is important to fully understand what the diagnosis is, as that is the first step to safety.

Surgeons often treat routine fibroids with minimally invasive techniques. These methods break or chop the tissue into smaller fragments so it can be pulled through tiny incisions. If a growth, however, turns out to be an unsuspected sarcoma, breaking it apart inside the pelvis can spread malignant cells. A thorough diagnostic workup beforehand makes sure nothing gets disrupted accidentally, so that the surgical team builds the safest possible treatment plan.

What You Need to Know About Fibroids

Here is some genuine peace of mind: benign fibroids don't suddenly turn into cancer. Medical research shows that malignant transformation inside an existing fibroid is exceptionally rare. Because fibroids and sarcomas are biologically different conditions from the start, monitoring a standard fibroid does not put you at risk of it turning into a tumor down the line.

Most fibroids stay completely harmless throughout life. It is, however, important to watch out for a few specific red flags:

Post-menopause changes: Fibroids shrink on their own once hormone levels drop after menopause. Any new growth or spotting at this stage demands a closer look.

Growths that keep expanding on medication: If a mass gets bigger while one is on prescriptions designed to shrink it, the patient must seek out a secondary review.

Ambiguous scans: When a routine ultrasound shows atypical tissue structure, stepping up to advanced imaging helps clear up the picture.

Next Steps and Second Opinions

Following an ultrasound, it is recommended to opt for a dedicated pelvic MRI for a much sharper view of the uterine muscle wall to confirm whether a mass is truly benign.

Getting a second opinion from a specialist is a normal, proactive move. It is especially critical if:

• A mass grows rapidly after menopause.

• A patient develops new pelvic symptoms or bleeding years after your period has stopped.
• The scans are flagged as atypical or difficult to read.

The good news is that uterine sarcomas are remarkably rare, making up just 2% to 5% of all uterine cancers. A patient needs to be cognizant by paying attention to changes in the body and asking questions about the scans.

Dr Bindhu KS - Sr. Consultant Obstetrics, Gynaecology & Robotic Surgery, Apollo Hospitals Navi Mumbai

For many women, polycystic ovary syndrome (PCOS) begins with a familiar story—irregular periods, acne, unwanted hair growth or difficulty conceiving. But PCOS is far more than a reproductive disorder. At its core, it is often a complex interplay between metabolism, hormones and reproductive health.

One of the most important, yet frequently overlooked, pieces of this puzzle is insulin resistance. When the body becomes less responsive to insulin, the pancreas compensates by producing more.

Elevated insulin levels can, in turn, contribute to increased androgen production by the ovaries and disrupt the delicate hormonal signals required for regular ovulation. The result may be irregular cycles, fewer ovulations and, for some women, difficulty becoming pregnant.

PCOS And Insulin Resistance Can Affect Women Of Any Weight

Importantly, PCOS and insulin resistance are not synonymous with obesity. Women with a healthy body weight can also have significant metabolic abnormalities. This is why judging metabolic health by appearance alone can be misleading.

The 2023 International Evidence-based PCOS Guideline recognises insulin resistance as an important underlying feature and recommends attention to metabolic risk across the weight spectrum.

Also read: Decoding The Fertility Markers

The Metabolic Risks Go Beyond Fertility

The metabolic implications extend well beyond fertility. Women with PCOS have a higher risk of impaired glucose tolerance and type 2 diabetes, making long-term metabolic surveillance an important part of care.

The guideline recommends appropriate glycaemic assessment, particularly when pregnancy is being planned or fertility treatment is being considered.

Also read: Can Regular Consumption of Junk and Processed Food Affect Fertility?

Building A Healthier Foundation For Pregnancy

Yet there is an equally important message of hope: PCOS does not mean infertility, nor does it have to define a woman’s health journey. Lifestyle interventions—including regular physical activity, nutritious eating, adequate sleep and sustainable weight management where appropriate—form the foundation of care and can improve metabolic health.

For a woman planning pregnancy, the goal should not simply be to “get pregnant.” It should be to enter pregnancy metabolically and emotionally healthier, with blood sugar, blood pressure, nutrition, lifestyle and other risk factors appropriately addressed.

Take-home message: PCOS is not merely about irregular periods or cysts on the ovaries. It is a lifelong condition in which metabolic health and reproductive health are deeply connected. Recognising insulin resistance early, looking beyond weight, and providing personalised care can help women protect both their fertility today and their health for years to come.